BACKGROUND: In spite of recent major advances in the understanding and treatment of inhibitor development in patients with haemophilia, multidisciplinary management of many of these patients remains suboptimal and highly heterogenous across Europe. METHODS: Following a series of multidisciplinary meetings and a review of the literature, the European haemophilia community of health professionals and patients jointly defined practical optimum standards for ensuring and harmonizing treatment and care for patients with an inhibitor. RESULTS: Ten complementary principles for the management of inhibitors in haemophilia have been developed, emphasizing the importance and benefits of a centralized, multidisciplinary, expert and holistic approach. CONCLUSIONS: This document will serve as a benchmark to improve the multidisciplinary and practical management of patients with inhibitor. Implementation and adherence to each of these principles should have a major positive impact on the management and outcomes of patients developing an inhibitor.

Canterbury Christ Church University Kent UK

Children's University Hospital Brno Brno Czech Republic

Department of Rehabilitation Nursing Science and Sports University Medical Center Utrecht Utrecht The Netherlands

European Haemophilia Consortium Rue de l'Industrie B 1000 Brussels Belgium

Haemostasis and Thrombosis Unit Division of Haematology Cliniques Universitaires Saint Luc Brussels Belgium

National Hemophilia Center Department of Hematology and Transfusion Medicine School of Medicine of Comenius University and University Hospital Bratislava Slovakia

Trinity College Dublin Ireland

University of Oxford Oxford UK

Zobrazit více v PubMed

Soucie J, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol. 1998;59:288–294. doi: 10.1002/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I. PubMed DOI

Astermark J. Overview of inhibitors. Semin Hematol. 2006;43(Suppl. 4):S3–S7. doi: 10.1053/j.seminhematol.2006.03.006. PubMed DOI

Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122:1954–1962. doi: 10.1182/blood-2013-02-483263. PubMed DOI

Colvin B, Astermark J, Fischer K, Gringeri A, Lassila R, et al. European principles of care. Haemophilia. 2008;14:361–374. doi: 10.1111/j.1365-2516.2007.01625.x. PubMed DOI

Mancuso ME, Mannucci PM, Rocino A, Garagiola A, Tagliaferri A, Santagostino E. Source and purity of factor VIII products as risk factor for inhibitor development in patients with hemophilia A. J Thromb Haemost. 2012;10:781–790. doi: 10.1111/j.1538-7836.2012.04691.x. PubMed DOI

van Velzen AS, Eckhardt CL, Peters M, Leebeek FWG, Escuriola C, Hermans C, Keenan R, Astermark J, Male C, Peerlinck K, le Cessie S, van der Bom JG, Fijnvandraat K, for the INSIGHT consortium Intensity of factor VIII treatment and the development of inhibitors in nonsevere hemophilia A patients: results of the INSIGHT case-control study. J Thromb Haemost. 2017;15:1422–1429. doi: 10.1111/jth.13711. PubMed DOI

Oldenburg J, Schroder J, Brackmann H, Müller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004;41(1 Suppl. 1):82–88. doi: 10.1053/j.seminhematol.2003.11.016. PubMed DOI

Mannucci PM, Mancuso ME, Franchini M. Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe haemophilia A. J Thromb Haemost. 2016;14:1330–1336. doi: 10.1111/jth.13356. PubMed DOI

Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalafy M, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374:2054–2064. doi: 10.1056/NEJMoa1516437. PubMed DOI

Hay CR, Palmer BP, Chalmers EA, Liesner R, Rangarajan S, Talks K, et al. The incidence of factor VIIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain deleted factor VIII: a prospective cohort comparison. Haemophilia. 2015;21:219–226. doi: 10.1111/hae.12563. PubMed DOI

Hay CR, Palmer B, Chalmers E, Liesner R, Maclean R. Incidence of factor VIII inhibitors throughout life in severe haemophilia A in the United Kingdom. Blood. 2011;117:6367–6370. doi: 10.1182/blood-2010-09-308668. PubMed DOI

Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser- Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995;73:247–251. PubMed

Miller CH. Improving the performance of factor VIIII inhibitor tests in hemophilia A. Thromb Res. 2015;136:1047–1048. doi: 10.1016/j.thromres.2015.09.019. PubMed DOI PMC

de Moerloose P, Fischer K, Lambert T, Windyga J, Batorova A, et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia. 2012;18:319–325. doi: 10.1111/j.1365-2516.2011.02671.x. PubMed DOI

Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia. Br J Haematol. 2013;160:153–170. doi: 10.1111/bjh.12091. PubMed DOI

Giangrande P, Calizzani G, Menichini I, Candura F, Mannucci PM, Makris M. The European standards of Haemophilia Centres. Blood Transfus. 2014;12(Suppl. 3):s525–s530. PubMed PMC

Matino D, Makris M, Dwan K, D’Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2015; 10.1002/14651858.CD004449.pub4. PubMed PMC

Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, et al. A randomized comparison of bypassing in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative Study (FENOC) Blood. 2007;109:546–551. doi: 10.1182/blood-2006-04-017988. PubMed DOI

Jiménez-Yuste V, Alvares MT, Martín-Salces M, Quintana M, Rodriguez-Merchan C, et al. Prophylaxis in 10 patients with haemophilia A and inhibitor: different approaches for different clinical situations. Haemophilia. 2009;15:203–209. doi: 10.1111/j.1365-2516.2008.01915.x. PubMed DOI

Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119:1335–1344. doi: 10.1182/blood-2011-08-369132. PubMed DOI

van Velzen AS, Eckhardt CL, Hart DP, Peters M, Rangarajan S, et al. Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thromb Haemost. 2015;114:46–55. doi: 10.1160/TH14-11-0940. PubMed DOI

Rangarajan S, Austin A, Goddard NJ, Négrier C, Rodriguez-Merchan EC, Stephensen D, et al. Consensus recommendations for the use of FEIBA in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia. 2013;19:294–303. doi: 10.1111/hae.12028. PubMed DOI

Santagostino E, Escobar M, Ozelo M, Arkhammar P, Lee H-Y, Rosu G, Giangrande P. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. Blood Rev. 2015;29(Suppl 1):S9–18. doi: 10.1016/S0268-960X(15)30003-5. PubMed DOI

Anderson JA, Brewer A, Creagh D, Hook S, Mainwaring J, et al. Guidance on the dental management of patients with haemophilia and congenital bleeding disorders. Br Dent J. 2013;215:497–450. doi: 10.1038/sj.bdj.2013.1097. PubMed DOI

Schrijvers L, Bedford M, Elfvinge P, Andritschke K, Leenders B, Harrington C, et al. The role of the European haemophilia nurse. J Haemophilia Pract. 2014;1:24–27. doi: 10.17225/jhp.00008. PubMed DOI

Harrington C, Bedford M, Andritschke K, Barrie A, Elfvinge P, Grønhaug S, Mueller-Kagi E, Leenders B, Schrivers L. A European curriculum for nurse working in haemophilia. Haemophilia. 2016;22:103–109. doi: 10.1111/hae.12785. PubMed DOI

Lindvall K, von Mackensen S, Elmståhl S, Khair K, Stain AM, Ljung R, Berntorp E. Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatr Blood Cancer. 2014;61:706–711. doi: 10.1002/pbc.24856. PubMed DOI

Bladen M. Chapter 14: inhibitors in children: functional consequences: 128-135. In: de Kleijn P, Mauser-Bunschoten EP, editors. Physiotherapy management in haemophilia. Utrecht: HH Global/GVO; 2017.

Bladen M, Main E, Hubert N, Koutomanou E, Liesner R, Khair K. Factors affecting the Hemophilia Joint Health Score in children with severe haemophilia. Haemophilia. 2013;19:626–631. doi: 10.1111/hae.12108. PubMed DOI

Sørensen B, Benson GM, Bladen M, Classey S, Keeling DM, et al. Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world. Haemophilia. 2012;18:598–606. doi: 10.1111/j.1365-2516.2011.02720.x. PubMed DOI

Canclini M, Saviolo-Negrin N, Zanon E, Bertoletti R, Girolami A, Pagnan A. Psychological aspects and coping in haemophilic patients: a case-control study. Haemophilia. 2003;9:619–624. doi: 10.1046/j.1365-2516.2003.00807.x. PubMed DOI

Cassis FR. Psychosocial care for people with hemophilia. Montreal: World Federation of Hemophilia; 2007.

Berntorp E. Future of haemophilia outcome assessment: registries are key to optimized treatment. J Int Med. 2016;279:498–501. doi: 10.1111/joim.12504. PubMed DOI

European principles of inhibitor management in patients with haemophilia: implications of new treatment options

Social support and resilience in persons with severe haemophilia: An interpretative phenomenological analysis